Investor Presentation

November 2022

Disclaimer

This presentation (the "Presentation") was prepared by Marinomed Biotech AG.

The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of this information or opinions contained herein. Neither Marinomed Biotech AG nor any officer or employee of Marinomed Biotech AG or any person connected with them accepts any liability whatsoever for any direct, indirect or consequential damages or losses arising from any use of this Presentation or its contents or otherwise arising in connection therewith. Marinomed Biotech AG undertakes no obligation to update or correct any information contained herein or to otherwise advise as to any future changes to it.

Certain statements contained in this document may be statements of future expectations and other forward looking statements that are

based on management's current view and assumptions and involve known and unknown risks and uncertainties that could cause actual

results, performance or events to differ materially from those expressed or implied in such statements.

Certain figures in this presentation have been rounded in accordance with commercial principles and practice. Such figures that have been rounded in various tables may not necessarily add up to the exact total given in the respective table.

This Presentation does not constitute or contain any investment advice. It is not and shall not be construed as an offer, invitation, recommendation or solicitation to sell, issue, purchase or subscribe for any securities in any jurisdiction or to enter into any transaction.

By accessing this Presentation, you represent, warrant and undertake that you have read and agree to comply with and to be bound by the contents of this disclaimer.

© Marinomed Biotech AG

2

Marinomed investment highlights

Solid existing business, broad late-stage pipeline

  • Highly experienced managementteam
  • Solid growth perspective with existing product portfolio
  • Lean and efficient business model - with cost efficient approach along entire value chain
  • Focus on of early clinical data to facilitate partnering with milestones and royalties
  • Long term growth perspective with Marinosolv products and SOLV4U business unit

© Marinomed Biotech AG

3

Marinomed management and ownership

Total number of shares

13.7%

1,506,162

8.4%

Acropora Beteiligungs GmbH

8.1%

Dr. Hermann Unger

61.7%

8.1%

DI Dr. Andreas Grassauer (CEO)

Mag. Dr. Eva Prieschl-Grassauer (CSO)

Free Float

PrimeMarketoftheVienna Stockexchange

MARI:AV; ATMARINOMED6; MARI.VI - part of ATPX, AP8, AXGP, NAP8, TAP8, WBI

Left to right:

Pascal Schmidt, CFO; Eva Prieschl-Grassauer, CSO and co-founder; Andreas Grassauer, CEO and co-founder

Team with long industry expertise and background

© Marinomed Biotech AG

Note: Rounding differences possible

4

Marinomed has built a proven track record

Successes in the therapeutic areas

Virology

  • Carragelose effective against respiratoryviruses
  • Series of clinicalstudies supports efficacy
  • Generating sustainable revenues and contribution margins
  • Patent protected
  • Marketed via partners in >40 countries

South East Asia

Immunology

  • First aqueous steroidsolution, all other major competitors are suspensions

Suspension

Solution

  • Dose reduced by >85% compared to originator
  • Primary and secondary endpoint met in successful clinicalPhase III
  • Patent protected
  • Partnered

© Marinomed Biotech AG

5

Attachments

  • Original Link
  • Original Document
  • Permalink

Disclaimer

Marinomed Biotech AG published this content on 11 November 2022 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 14 November 2022 11:11:03 UTC.